David A. Frank
MD, PhD, FACP
Board certified in medical oncology, Dr. Frank cares for patients with hematologic malignancies, specializing in leukemia.
Specialty
A renowned physician-scientist, Dr. Frank's research has developed innovative ways to target STAT transcription factors for the treatment of cancer.
Titles and Roles
- Director, Division of Hematology, Department of Hematology and Medical Oncology
- Emory University School of Medicine
- Professor, Department of Hematology and Medical Oncology
- Emory University School of Medicine
- Research Program
- Discovery and Developmental Therapeutics
Biography
David A. Frank, MD, PhD, FACP, is the director of the Division of Hematology and a professor in Emory University School of Medicine's Department of Hematology and Medical Oncology. He also serves as director of the Winship Innovation Initiative and as an advisor to the Morningside Center for Innovative and Affordable Medicine within the Woodruff Health Sciences Center. Board certified in medical oncology, he cares for patients with hematologic malignancies, specializing in leukemia. He is actively involved in training the next generation of clinical oncologists and cancer scientists.
Dr. Frank is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. He is a Fellow of American College of Physicians. He holds professional memberships with American Association for the Advancement of Science, American Association of Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Microbiology. He serves as chair for the Medical Sciences Section of the American Association for the Advancement of Science.
Prior to joining Emory, Dr. Frank was the chief quality officer for Dana-Farber/Harvard Cancer Center, having previously served as chair of Quality Improvement for Medical Oncology, chair of the Pharmacy and Therapeutics Committee, and medical director of patient safety.
Education
Dr. Frank received his MD and PhD from Yale University. After serving as an intern, resident, and chief resident in internal medicine at Yale, he completed training in medical oncology at Dana-Farber Cancer Institute, followed by a postdoctoral fellowship in intracellular signal transduction at Harvard Medical School.
Research
A renowned physician-scientist, Dr. Frank's translational research laboratory focuses on the intracellular signaling pathways that control normal cellular function and become subverted in the development of cancer, and then using this knowledge in designing targeted molecular inhibitors for the treatment of cancer. His lab has developed innovative ways to target STAT transcription factors, leading to a series of therapeutic clinical trials, including the first clinical trial of a small molecule STAT3 inhibitor in cancer therapy.
Publications
Dr. Frank has authored or coauthored more than 100 peer-reviewed publications. He serves on the editorial board of Cancer Research, Clinical Cancer Research, and Cancer Biology and Therapy. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, Nature Medicine, Science Signaling, Proceedings of the National Academy of Sciences, and others.
Publications Publication Date